In breast cancer cells that exhibit high HLA-G expression, binding to KIR2DL4 on natural killer (NK) cells suppresses their anti-tumor activity, thereby reducing the therapeutic efficacy of trastuzumab. Here, KIR2DL4 is linked to breast carcinoma.